Skip to main content
. 2016 Nov 11;6:36843. doi: 10.1038/srep36843

Figure 3. CUDR enhances SUV39h2 expression in hepatocyte-like stem cells with IL6 treatment.

Figure 3

(a) Chromatin Immunoprecipitation (CHIP) with anti-CREPT, anti-RNA PolII followed by PCR with SUV39h2 promoter primers in hepatocyte-like stem cells treated with IL6 and transfected with pCMV6-A-GFP, pCMV6-A-GFP-CUDR, pGFP-V-RS, pGFP-V-RS-CUDR. IgG CHIP as negative control. SUV39h2 promoter DNA as INPUT. (b) SUV39h2 promoter luciferase activity assay. Each value was presented as mean ± standard error of the mean (SEM). **P < 0.01. (c) RNA Immunoprecipitation (RIP) with anti-METTL3 followed by RT-PCR with SUV39h2 primers. IgG RIP as negative control. SUV39h1 mRNA as INPUT. (d) RNA Immunoprecipitation (RIP) with anti-N6Ame followed by RT-PCR with SUV39h2 mRNA primers. IgG RIP as negative control. SUV39h1 mRNA as INPUT. (e) SUV39h2 expression analysis by RT-PCR. β-actin as internal control. (f) The analysis of SUV39h2 expression, SUV39h2 phosorylation and SUV39h2 sumoylation by western blotting with anti-SUV39h2, anti-pSUV39h2, β-actin as internal control, or IP with anti-SUV39h2 and anti-SUM western blotting. Western blotting with anti-SUV39h2 was uesd as INPUT.